Literature DB >> 29338971

Atorvastatin impaired glucose metabolism in C2C12 cells partly via inhibiting cholesterol-dependent glucose transporter 4 translocation.

Binbin Sun1, Zeyu Zhong1, Fan Wang1, Jiong Xu1, Feng Xu1, Weimin Kong1, Zhaoli Ling1, Nan Shu1, Ying Li1, Tong Wu1, Mian Zhang1, Liang Zhu1, Xiaodong Liu2, Li Liu3.   

Abstract

Skeletal muscle accounts for approximately 75% of glucose disposal in body and statins impair glucose metabolism. We aimed to investigate the effect of atorvastatin on glucose metabolism in C2C12 cells. Glucose metabolism and expression of glucose transporter 4 (GLUT4) and hexokinase II (HXKII) were measured following incubation with atorvastatin or pravastatin. Roles of cholesterol in atorvastatin-induced glucose metabolism impairment were investigated via adding cholesterol or mevalonic acid and confirmed by cholesterol depletion with methyl-β-cyclodextrin. Hypercholesterolemia mice induced by high fat diet (HFD) feeding, orally received atorvastatin (6 and 12 mg/kg) or pravastatin (12 mg/kg) for 22 days. Results showed that atorvastatin not pravastatin concentration-dependently impaired glucose consumption, glucose uptake and GLUT4 membrane translocation in C2C12 cells without affecting expression of HXKII or total GLUT4 protein. The atorvastatin-induced alterations were reversed by cholesterol or mevalonic acid. Cholesterol depletion exerted similar impact to atorvastatin, which could be alleviated by cholesterol supplement. Glucose consumption or GLUT4 translocation was positively associated with cellular cholesterol levels. In HFD mice, atorvastatin not pravastatin significantly increased blood glucose levels following glucose or insulin dose and decreased expression of membrane not total GLUT4 protein in muscle. Glucose exposure following glucose or insulin dose was negatively correlated to muscular free cholesterol concentration. Expression of membrane GLUT4 protein was positively related to free cholesterol in muscle. In conclusion, atorvastatin impaired glucose utilization in muscle cells partly via inhibiting GLUT4 membrane translocation due to inhibition of cholesterol synthesis by atorvastatin, at least, partly contributing to glucose intolerance in HFD mice.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atorvastatin; Cholesterol; Diabetes; Glucose transporter 4; Muscle; Translocation

Mesh:

Substances:

Year:  2018        PMID: 29338971     DOI: 10.1016/j.bcp.2018.01.021

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

Review 1.  Updated Understanding of the Crosstalk Between Glucose/Insulin and Cholesterol Metabolism.

Authors:  Xuan Xiao; Yonghong Luo; Daoquan Peng
Journal:  Front Cardiovasc Med       Date:  2022-04-29

2.  PXR activation impairs hepatic glucose metabolism partly via inhibiting the HNF4α-GLUT2 pathway.

Authors:  Peihua Liu; Ling Jiang; Weimin Kong; Qiushi Xie; Ping Li; Xiaonan Liu; Jiayi Zhang; Ming Liu; Zhongjian Wang; Liang Zhu; Hanyu Yang; Ying Zhou; Jianjun Zou; Xiaodong Liu; Li Liu
Journal:  Acta Pharm Sin B       Date:  2021-10-16       Impact factor: 14.903

3.  In Vitro Effects of Emerging Bisphenols on Myocyte Differentiation and Insulin Responsiveness.

Authors:  Jiongjie Jing; Yong Pu; Almudena Veiga-Lopez; Lihua Lyu
Journal:  Toxicol Sci       Date:  2020-11-01       Impact factor: 4.849

Review 4.  Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights.

Authors:  Unai Galicia-Garcia; Shifa Jebari; Asier Larrea-Sebal; Kepa B Uribe; Haziq Siddiqi; Helena Ostolaza; Asier Benito-Vicente; César Martín
Journal:  Int J Mol Sci       Date:  2020-07-02       Impact factor: 5.923

5.  Effects of Astaxanthin on Inflammation and Insulin Resistance in a Mouse Model of Gestational Diabetes Mellitus.

Authors:  Weihong Feng; Yanxia Wang; Na Guo; Pu Huang; Yang Mi
Journal:  Dose Response       Date:  2020-05-20       Impact factor: 2.658

6.  Insulin prevents and reverts simvastatin-induced toxicity in C2C12 skeletal muscle cells.

Authors:  Gerda M Sanvee; Jamal Bouitbir; Stephan Krähenbühl
Journal:  Sci Rep       Date:  2019-05-15       Impact factor: 4.379

7.  Diabetogenic effect of pravastatin is associated with insulin resistance and myotoxicity in hypercholesterolemic mice.

Authors:  Estela Lorza-Gil; Marta García-Arevalo; Bianca Cristine Favero; Maria Cristina C Gomes-Marcondes; Helena C F Oliveira
Journal:  J Transl Med       Date:  2019-08-27       Impact factor: 5.531

Review 8.  Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?

Authors:  Mohamed J Nsaibia; Anichavezhi Devendran; Eshak Goubaa; Jamal Bouitbir; Romain Capoulade; Rihab Bouchareb
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

Review 9.  Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies.

Authors:  Magda Dubińska-Magiera; Marta Migocka-Patrzałek; Damian Lewandowski; Małgorzata Daczewska; Krzysztof Jagla
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

10.  Inhibiting miR-182-3p Alleviates Gestational Diabetes Mellitus by Improving Insulin Resistance in Skeletal Muscle.

Authors:  Jinghong Rao; Youfang Chen; Jingying Huang; Ruoying Wu; Zhenzhu Dong; Yuling Gao; Xuan Chen
Journal:  Balkan Med J       Date:  2022-03-14       Impact factor: 2.021

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.